Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06376240Not ApplicableCompleted

The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes

Role: collaborator

NCT04828304Not ApplicableCompleted

PLASOMA Ultimate Safety & Efficacy Study

Role: collaborator

NCT03049228Completed

In and ex Vivo Mitochondrial Function of the Heart

Role: collaborator

NCT02565979Not ApplicableCompleted

Long-term Resveratrol and Metabolism

Role: collaborator

NCT02129595Not ApplicableCompleted

Resveratrol and First-degree Relatives of Type 2 Diabetic Patients

Role: collaborator

All 5 trials loaded